Peginterferon 2a for the treatment of HIV infection

David M. Asmuth, Netanya S. Utay, Richard B. Pollard

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Introduction: Novel approaches are urgently needed to achieve the next level of control of HIV infection beyond antiretroviral medications that will lead to the ultimate goal of curing HIV infection. Exploiting the innate immune system control of HIV is one possible component of that strategy with pegylated interferon representing a well-characterized agent that is being applied to this effort.Areas covered: In this review, the authors summarize the history of interferon treatment in the setting of HIV infection with a focus on clinical trials that examined the downstream effects on innate immune responses. More recently, clinical trials that administered pegylated interferon 2a have demonstrated which interferon-stimulated genes are associated with its antiviral effects and which of these host-restriction factors may play a role in limiting the magnitude of the HIV reservoir.Expert opinion: The potential to exploit interferon as part of a cure strategy is provocative. Whether key interferon-induced antiviral factors can be upregulated sufficiently to affect the reservoir is unknown. Additional research employing pegylated interferon 2a is needed to identify which innate immune pathways are candidate targets for novel biological therapies for the potential cure of HIV infection.

Original languageEnglish (US)
Pages (from-to)249-257
Number of pages9
JournalExpert Opinion on Investigational Drugs
Volume25
Issue number2
DOIs
StatePublished - Feb 1 2016

Fingerprint

Interferons
HIV Infections
Therapeutics
Antiviral Agents
Clinical Trials
HIV
Biological Therapy
Expert Testimony
Innate Immunity
Immune System
History
Research
Genes

Keywords

  • HIV
  • HIV reservoir
  • humans
  • innate immune system
  • Interferon alpha
  • interferon stimulated genes
  • review

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Peginterferon 2a for the treatment of HIV infection. / Asmuth, David M.; Utay, Netanya S.; Pollard, Richard B.

In: Expert Opinion on Investigational Drugs, Vol. 25, No. 2, 01.02.2016, p. 249-257.

Research output: Contribution to journalArticle

Asmuth, David M. ; Utay, Netanya S. ; Pollard, Richard B. / Peginterferon 2a for the treatment of HIV infection. In: Expert Opinion on Investigational Drugs. 2016 ; Vol. 25, No. 2. pp. 249-257.
@article{21d7f178750d44db9ab30cfaccd244d7,
title = "Peginterferon 2a for the treatment of HIV infection",
abstract = "Introduction: Novel approaches are urgently needed to achieve the next level of control of HIV infection beyond antiretroviral medications that will lead to the ultimate goal of curing HIV infection. Exploiting the innate immune system control of HIV is one possible component of that strategy with pegylated interferon representing a well-characterized agent that is being applied to this effort.Areas covered: In this review, the authors summarize the history of interferon treatment in the setting of HIV infection with a focus on clinical trials that examined the downstream effects on innate immune responses. More recently, clinical trials that administered pegylated interferon 2a have demonstrated which interferon-stimulated genes are associated with its antiviral effects and which of these host-restriction factors may play a role in limiting the magnitude of the HIV reservoir.Expert opinion: The potential to exploit interferon as part of a cure strategy is provocative. Whether key interferon-induced antiviral factors can be upregulated sufficiently to affect the reservoir is unknown. Additional research employing pegylated interferon 2a is needed to identify which innate immune pathways are candidate targets for novel biological therapies for the potential cure of HIV infection.",
keywords = "HIV, HIV reservoir, humans, innate immune system, Interferon alpha, interferon stimulated genes, review",
author = "Asmuth, {David M.} and Utay, {Netanya S.} and Pollard, {Richard B.}",
year = "2016",
month = "2",
day = "1",
doi = "10.1517/13543784.2016.1132699",
language = "English (US)",
volume = "25",
pages = "249--257",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Taylor and Francis Ltd.",
number = "2",

}

TY - JOUR

T1 - Peginterferon 2a for the treatment of HIV infection

AU - Asmuth, David M.

AU - Utay, Netanya S.

AU - Pollard, Richard B.

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Introduction: Novel approaches are urgently needed to achieve the next level of control of HIV infection beyond antiretroviral medications that will lead to the ultimate goal of curing HIV infection. Exploiting the innate immune system control of HIV is one possible component of that strategy with pegylated interferon representing a well-characterized agent that is being applied to this effort.Areas covered: In this review, the authors summarize the history of interferon treatment in the setting of HIV infection with a focus on clinical trials that examined the downstream effects on innate immune responses. More recently, clinical trials that administered pegylated interferon 2a have demonstrated which interferon-stimulated genes are associated with its antiviral effects and which of these host-restriction factors may play a role in limiting the magnitude of the HIV reservoir.Expert opinion: The potential to exploit interferon as part of a cure strategy is provocative. Whether key interferon-induced antiviral factors can be upregulated sufficiently to affect the reservoir is unknown. Additional research employing pegylated interferon 2a is needed to identify which innate immune pathways are candidate targets for novel biological therapies for the potential cure of HIV infection.

AB - Introduction: Novel approaches are urgently needed to achieve the next level of control of HIV infection beyond antiretroviral medications that will lead to the ultimate goal of curing HIV infection. Exploiting the innate immune system control of HIV is one possible component of that strategy with pegylated interferon representing a well-characterized agent that is being applied to this effort.Areas covered: In this review, the authors summarize the history of interferon treatment in the setting of HIV infection with a focus on clinical trials that examined the downstream effects on innate immune responses. More recently, clinical trials that administered pegylated interferon 2a have demonstrated which interferon-stimulated genes are associated with its antiviral effects and which of these host-restriction factors may play a role in limiting the magnitude of the HIV reservoir.Expert opinion: The potential to exploit interferon as part of a cure strategy is provocative. Whether key interferon-induced antiviral factors can be upregulated sufficiently to affect the reservoir is unknown. Additional research employing pegylated interferon 2a is needed to identify which innate immune pathways are candidate targets for novel biological therapies for the potential cure of HIV infection.

KW - HIV

KW - HIV reservoir

KW - humans

KW - innate immune system

KW - Interferon alpha

KW - interferon stimulated genes

KW - review

UR - http://www.scopus.com/inward/record.url?scp=84957437563&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957437563&partnerID=8YFLogxK

U2 - 10.1517/13543784.2016.1132699

DO - 10.1517/13543784.2016.1132699

M3 - Article

C2 - 26667398

AN - SCOPUS:84957437563

VL - 25

SP - 249

EP - 257

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 2

ER -